Document is current
Any future updates will be listed below
-
Authors
Wang, Fangfang
Luan, Zijian
Maltesen, Raluca
Reenberg, Asbjørn T.
Westergaard, Lisbet
Liu, Dongyang https://orcid.org/0000-0002-0608-8192
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05435677 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic Characteristics of a Once-Weekly Combination Therapy of Insulin Icodec and Semaglutide Versus Its Separate Components in Chinese Individuals with Type 2 Diabetes
https://doi.org/10.1007/s13300-025-01803-x
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 12 August 2025
Accepted: 19 September 2025
First Online: 6 October 2025
Declarations
:
: Zijian Luan, Raluca Maltesen, Asbjørn T Reenberg and Lisbet Westergaard are employees and shareholders of Novo Nordisk. Dongyang Liu and Fangfang Wang declare no conflicts of interest.
: The protocol for this study was approved by a suitably constituted independent ethics committee (Ethics Committee of Peking University Third Hospital, Beijing, China). The study was conducted according to the principles of the Helsinki Declaration of 1964 and its later amendments and ICH Good Clinical Practice []. All participants provided informed consent.
